`
`Page 1 of 4
`
`8-K 1 form8-k.htm IMMUNOGEN, INC. FORM 8-K
`UNITED STATES
`SECURITIES AND EXCHANGE COMMISSION
`
`Washington, D.C. 20549
`
`FORM 8-K
`
`CURRENT REPORT
`
`PURSUANT TO SECTION 13 OR 15(d)
`OF THE SECURITIES EXCHANGE ACT OF 1934
`
`Date of Report (Date of earliest event reported): January 25, 2006
`
`ImmunoGen, Inc.
`
`(Exact name of registrant as specified in its charter)
`
`Massachusetts
`(State or other jurisdiction of incorporation)
`
`0-17999
`(Commission File Number)
`
`04-2726691
`(IRS Employer Identification No.)
`
`128 Sidney Street, Cambridge, MA 02139
`(Address of principal executive offices) (Zip Code)
`
`Registrant's telephone number, including area code: (617) 995-2500
`
`Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
`registrant under any of the following provisions (see General Instruction A.2. below):
`
`(cid:134)
`
`(cid:134)
`
`(cid:134)
`(17 CFR 240.14d-2(b))
`
`(cid:134)
`(17 CFR 240.13e-4(c))
`
`Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
`
`Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
`
`Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
`
`Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
`
`https://www.sec.gov/Archives/edgar/data/855654/000085565406000002/form8-k.htm
`
`9/30/2016
`
`
`
`JANSSEN EXHIBIT 2084
`Wockhardt v. Janssen IPR2016-01582
`
`
`
`ImmunoGen, Inc. form 8-K
`
`Page 2 of 4
`
`ITEM 8.01 - OTHER EVENTS
`
`On January 25, 2006, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) notified ImmunoGen, Inc. (Nasdaq:
`IMGN) that as part of its ongoing portfolio management process and based on the evaluation of recent clinical data in the
`context of other opportunities in its pipeline, Millennium had decided not to continue the development of its MLN2704
`compound. MLN2704 consists of a Millennium antibody to the Prostate-Specific Membrane Antigen (PSMA) and
`ImmunoGen’s DM1 and was in development by Millennium under a 2001 agreement that gave Millennium rights to use
`ImmunoGen’s maytansinoid Tumor-Activated Prodrug (TAP) technology with antibodies targeting PSMA. On January
`26, 2006, Millennium publicly disclosed that it had discontinued development of MLN2704 and that it was in the process
`of evaluating whether to continue development of this antibody conjugated with other cell-killing agents including other
`maytansanoids. Millennium retains its right to use ImmunoGen’s maytansinoid TAP technology with antibodies targeting
`PSMA.
`
`2
`
`https://www.sec.gov/Archives/edgar/data/855654/000085565406000002/form8-k.htm
`
`9/30/2016
`
`
`
`ImmunoGen, Inc. form 8-K
`
`Page 3 of 4
`
`SIGNATURES
`
`Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be
`signed on its behalf by the undersigned hereunto duly authorized.
`
`Date: January 26, 2006
`
`ImmunoGen, Inc.
`(Registrant)
`
`/s/ Karleen M. Oberton
`
`Karleen M. Oberton
`Senior Corporate Controller
`(Principal Accounting Officer)
`
`3
`
`https://www.sec.gov/Archives/edgar/data/855654/000085565406000002/form8-k.htm
`
`9/30/2016
`
`
`
`ImmunoGen, Inc. form 8-K
`
`Page 4 of 4
`
`https://www.sec.gov/Archives/edgar/data/855654/000085565406000002/form8-k.htm
`
`9/30/2016
`
`